Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...
BofA initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $15 price target Candel’s pipeline includes two lead drugs – ...
Stocktwits on MSN17h
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' CallShares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback